Drug intelligence / Profile preview

kuding saponin A

Development stage: Unknown
Lead developer: 上海凯屹医药科技
Modality: Small Molecules
Administration: Inhalation

Overview

Kuding saponin A is a small molecule chemical drug developed as an inhalation solution for the treatment of respiratory diseases, specifically bronchial asthma and chronic obstructive pulmonary disease (COPD). Developed by Shanghai Kaiyi Pharmaceutical Technology, a subsidiary of Zhejiang Wolwo Bio-Pharmaceutical (Wolwo Biotech), the drug is a purified saponin derived from the Chinese herb Kudingcha (*Ilex kudingcha*). It functions as a bronchodilator, with research indicating its mechanism involves the activation of bitter taste receptors (TAS2Rs) located on airway smooth muscle cells, which triggers muscle relaxation. The candidate is currently in Phase 2 clinical development in China.

Other names: Kudingcha Saponin A Inhalation Solution苦丁皂苷A吸入溶液

Targets

TAS2R (Taste receptor type 2 family)

Beyond the preview

Go deeper on kuding saponin A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on kuding saponin A.

Explore the full profile